whitepaper
Application note: Validation of identified through AI
Targets for drug discovery can be identified with AI but require validation in vitro. Here’s how this can be done, using hiPSC technology.
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
webinar
Leveraging innovative strategies for speedy cell line development
1 October 2021 | By Sartorius
Watch this roundtable of industry experts as they discuss technologies, best practices and strategies for delivering robust, stable, high-yielding cell lines to accelerate and streamline the drug discovery process.
article
Targeting SARS-CoV-2 replication with inhibitors of lipid metabolism
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
article
High-throughput 3D cell migration assays in organ-on-a-chip technologies
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
article
Drug Target Review Assays ebook 2021
Included in this ebook are articles exploring the discovery of therapeutics that can be repurposed against COVID-19 and discussing a novel assay approach for the identification of drug targets using mass spectrometry.
article
Drug Target Review Synthetic Biology ebook 2021
In this ebook, discover why CRISPR can aid the development of new drugs via loss-of-function screens and how the field of synthetic biology is likely to evolve within the context of health.
article
Drug Target Review – Issue 3 2021
In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies.
whitepaper
Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
news
Novel technology could significantly advance genomics field
New technology system of drug-based markers for the selection or counter-selection of genes may advance genetic screening methods.
news
New screening method identifies COVID-19 protein inhibitor
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
article
Sample preparation automation in label-free compound profiling
Following the latest Drug Target Review webinar, supported by Analytik Jena, we put the audience’s questions to the speakers to understand how hardware, software and labware challenges can be successfully overcome.
whitepaper
Whitepaper: Accelerate antibody screening and characterisation
This whitepaper overviews use of Advanced Flow Cytometry to accelerate antibody screening and characterisation and reveal deeper biological insights.
news
AI method reveals 17 existing drugs that may fight against COVID-19
Scientists used artificial intelligence to identify 17 existing drugs that could kill SARS-CoV-2 in cells, including a dietary supplement.
webinar
Accelerating drug discovery using novel screening technologies
19 August 2021 | By 10X Genomics
Explore the latest developments in screening technologies and how drug discovery has changed during the past decades in our webinar with 10X Genomics.
webinar
Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
19 August 2021 | By Eurofins Discovery
Watch this on-demand webinar that discusses the two assays developed by Eurofins and why they represent a more physiologic and dynamic system to provide a more comprehensive pre-clinical model for cardiac liability assessment.
